CompletedNCT00600795
Prognostic Value of Transforming Growth Factor-Beta 1 in Normal Pressure Hydrocephalus
Studying NON RARE IN EUROPE: Normal pressure hydrocephalus
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Vanderbilt University Medical Center
- Principal Investigator
- Noel Tulipan, M.D.Vanderbilt University Medical Center
- Intervention
- CSF collection(other)
- Enrollment
- 21 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2008 – 2011
Study locations (1)
- Vanderbilt University Medical Center, Nashville, Tennessee, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00600795 on ClinicalTrials.govOther trials for NON RARE IN EUROPE: Normal pressure hydrocephalus
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07427836Integrated Multimodal Assessment to Optimize Diagnosis and Surgical Selection in Idiopathic Normal Pressure HydrocephalusFondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
- RECRUITINGNCT05910944European Study of Prodromal iNPHJohan Virhammar
- RECRUITINGNCT06722768Identifying Gait Changes From a CSF Tap Test Using a Smart Insole in iNPHYonsei University
See all trials for NON RARE IN EUROPE: Normal pressure hydrocephalus →